Atara Biotherapeutics, Inc.

211 articles with Atara Biotherapeutics, Inc.

• Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

  12/7/2020

  Bayer and Atara Biotherapeutics, Inc. announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors.

• 

  Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration

  12/7/2020

  The collaboration with Atara will focus on developing an off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.

• Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

  11/16/2020

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences. Stifel 2020 Virtual Healthcare Conferenc

• Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting

  11/15/2020

  Long-term follow-up shows all patients who demonstrated sustained disability improvement (SDI) maintained it at all subsequent timepoints

• Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

  11/12/2020

  Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35 th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020) Atara’s allogeneic CAR T therapy leverages the combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies built on the Company’s novel EBV T-cell platform

• Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress

  11/9/2020

    Interim Analysis of the pivotal 302 study (ALLELE) showed tab-cel ® in EBV + PTLD achieved a 50 percent objective response rate and safety consistent with historical data Discussions with FDA confirmed Atara can complete BLA filing with the ALLELE study’s currently enrolled patients with at least six-months follow-up for duration of response

• 

  ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More

  9/18/2020

  Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.

• Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020

  9/14/2020

  Tab-cel® was well-tolerated and demonstrated encouraging clinical efficacy in previously treated patients with EBV+ AID-LPD and PID-LPD

• 

  Clinical Catch-Up: September 7-11

  9/14/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188

  9/11/2020

  Patients Who Achieved SDI at Any Timepoint Maintained it at All Future Timepoints; Higher Proportion of Patients Showing SDI with Increasing Dose Patients Achieving SDI Also Demonstrated Trend Toward Improvement in Fatigue and Physical Function at 12 Months First Available Data from Open Label Expansion Show Patients with SDI at 12 Months, Maintained SDI at Later Time Points Conference Call and Webcast Today, September 11, 2020 at 8:30

• Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors

  9/8/2020

  First CAR T therapy leveraging combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies to enter the clinic

• Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020

  9/1/2020

  Various Atara Posters Being Presented at ACTRIMS-ECTRIMS Further Elucidate the Role of EBV in MS Company to Host Live Conference Call and Webcast to Review MS Data Presentation on Friday, September 11, 2020 at 8:30 a.m. ET/5:30 p.m. CEST SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for pa

• Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress

  8/5/2020

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.

• Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020

  7/29/2020

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial results after market close on Wednesday, August 5, 2020.

• Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

  6/24/2020

  Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that the underwriters of its recently closed underwritten offering of 12,633,039 shares of its common stock

•  Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis

  6/17/2020

  Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis   Based on promising results from the Phase 1a study including sustained disability improvements among progressive MS patients, the Phase 1b study will assess clinical outcomes including measures of disability, physical and cognitive function, biomarkers and MRI imaging as well as safety

• Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format

  6/5/2020

  Atara Biotherapeutics, Inc . (Nasdaq: ATRA) today announced that, due to public health and safety concerns related to the coronavirus (“COVID-19”) pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual Meeting of Stockholders (“Annual Meeting”) as a virtual-only meeti

• Atara Biotherapeutics to Participate at Two Upcoming Conferences

  6/4/2020

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Pascal Touchon, the Company’s President and Chief Executive Officer, will participate at two upcoming virtual conferences in June.

• Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering

  5/27/2020

  Atara Biotherapeutics, Inc. announced the pricing of an underwritten public offering of 12,633,039 shares of its common stock at a price to the public of $11.32 per share and, to certain investors, pre-funded warrants to purchase 2,866,961 shares of its common stock at a purchase price of $11.3199 per pre-funded warrant share, which represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant share.

• Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

  5/26/2020

  Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of its common stock